Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma The European Organisation for Research and Treatment of Cancer...

por Penel, N, Glabbeke, M V, Mathoulin-Pelissier, S, Judson, I, Sleijfer, S, Bui, B, Schoffski, P, Ouali, M, Marreaud, S, Brouste, V, Duhamel, A, Hohenberger, P, Blay, J-Y
Publicado 2011

An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy

por Blaye, C., Darbo, É., Debled, M., Brouste, V., Vélasco, V., Pinard, C., Larmonier, N., Pellegrin, I., Tarricone, A., Arnedos, M., Commeny, J., Bonnefoi, H., Larmonier, C., MacGrogan, G.
Publicado 2022

High frequency of β-catenin heterozygous mutations in extra-abdominal fibromatosis: a potential molecular tool for disease management

por Dômont, J, Salas, S, Lacroix, L, Brouste, V, Saulnier, P, Terrier, P, Ranchère, D, Neuville, A, Leroux, A, Guillou, L, Sciot, R, Collin, F, Dufresne, A, Blay, J-Y, Le Cesne, A, Coindre, J-M, Bonvalot, S, Bénard, J
Publicado 2010